article thumbnail

MHRA Chief Executive to step down

European Pharmaceutical Review

Previous roles The MHRA highlighted Dame June Raine has been Chief Executive Officer of the MHRA since August 2019. Her educational background includes training in medicine in Oxford after completing a master’s degree by research in Pharmacology.

Safety 111
article thumbnail

Can Hepatitis C drugs reduce symptoms of PTSD?

European Pharmaceutical Review

The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. Many people have PTSD, but there [are] few effective pharmacologic treatments and limited drug development for PTSD,” commented Gradus. The findings are to be published in the American Journal of Epidemiology.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Early diagnosis in Alzheimer’s disease: A first step towards better care

Clarivate

Personalized care relies on pharmacological and non-pharmacological interventions aimed at (temporarily) relieving cognitive and non-cognitive symptoms (Alzheimer’s Association, n.d.; Creative Art Therapy as a Non-Pharmacological Intervention for Dementia: A Systematic Review. 2024; Quanterix, 2024). Emblad, S. Esquivel, R.

article thumbnail

Advancing AOCs to transform the delivery of RNA therapeutics

European Pharmaceutical Review

Known linkers in the RNA field are used to bond together the two pharmacologically active molecular entities and can be applied to multiple oligonucleotide modalities. 2019 ;42:385-406. Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging. Internet] Nature Portfolio. Antiviral agents.

Safety 98
article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.

Patients 105
article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

Xu gave the example of the FDA’s first approval of an AAV-based gene therapy for paediatric spinal muscular atrophy patients in 2019, saying that evidence of effectiveness generated from two single-arm externally controlled clinical trials in patients with infantile onset SMA was substantial enough for an approval.

FDA 105
article thumbnail

2022 in review: Drug development milestones for tropical diseases

Pharmaceutical Technology

This year saw great progress towards making new therapeutics for malaria available sooner rather than later, says Karen Barnes, PhD, professor at the University of Cape Town’s Division of Clinical Pharmacology. As per the WHO’s 2022 malaria report , 63,000 malaria deaths were attributed to Covid-19-caused disruptions to services from 2019–21.